Nanoparticle-Mediated Drug Delivery Systems for Precision Targeting in Oncology

被引：34

作者：

Hristova-Panusheva, Kamelia ^{[1
]}

Xenodochidis, Charilaos ^{[1
]}

Georgieva, Milena ^{[2
]}

Krasteva, Natalia ^{[1
]}

机构：

[1] Bulgarian Acad Sci, Inst Biophys & Biomed Engn, Acad Georgi Bonchev Str Bl 21, Sofia 1113, Bulgaria

[2] Bulgarian Acad Sci, Inst Mol Biol Acad R Tsanev, Acad Georgi Bonchev Str,Bl 21, Sofia 1113, Bulgaria

来源：

PHARMACEUTICALS | 2024年 / 17卷 / 06期

关键词：

nanotechnology; site-specific cancer therapy; personalized oncomedicine; cancer-cell-targeted nanomedicines; tumour microenvironment-targeted nanomedicines; BREAST-CANCER; IN-VITRO; GOLD NANOPARTICLES; TUMOR VASCULATURE; THERAPY; NANOMEDICINE; DOXORUBICIN; NANOTHERAPEUTICS; INHIBITION; DENDRIMER;

D O I：

10.3390/ph17060677

中图分类号：

R914 [药物化学];

学科分类号：

100701 ;

摘要：

Nanotechnology has emerged as a transformative force in oncology, facilitating advancements in site-specific cancer therapy and personalized oncomedicine. The development of nanomedicines explicitly targeted to cancer cells represents a pivotal breakthrough, allowing the development of precise interventions. These cancer-cell-targeted nanomedicines operate within the intricate milieu of the tumour microenvironment, further enhancing their therapeutic efficacy. This comprehensive review provides a contemporary perspective on precision cancer medicine and underscores the critical role of nanotechnology in advancing site-specific cancer therapy and personalized oncomedicine. It explores the categorization of nanoparticle types, distinguishing between organic and inorganic variants, and examines their significance in the targeted delivery of anticancer drugs. Current insights into the strategies for developing actively targeted nanomedicines across various cancer types are also provided, thus addressing relevant challenges associated with drug delivery barriers. Promising future directions in personalized cancer nanomedicine approaches are delivered, emphasising the imperative for continued optimization of nanocarriers in precision cancer medicine. The discussion underscores translational research's need to enhance cancer patients' outcomes by refining nanocarrier technologies in nanotechnology-driven, site-specific cancer therapy.

引用

页数：25

共 164 条

[11] Safety and Efficacy of BIND-014, a Docetaxel Nanoparticle Targeting Prostate-Specific Membrane Antigen for Patients With Metastatic Castration-Resistant Prostate Cancer A Phase 2 Clinical Trial [J].

Autio, Karen A. ;

Dreicer, Robert ;

Anderson, Justine ;

Garcia, Jorge A. ;

Alva, Ajjai ;

Hart, Lowell L. ;

Milowsky, Matthew I. ;

Posadas, Edwin M. ;

Ryan, Charles J. ;

Graf, Ryon P. ;

Dittamore, Ryan ;

Schreiber, Nicole A. ;

Summa, Jason M. ;

Youssoufian, Hagop ;

Morris, Michael J. ;

Scher, Howard I. .

JAMA ONCOLOGY, 2018, 4 (10) :1344-1351

[12]

Bakalova S.M., 2022, Lecture Notes in Computer Science, Proceedings of the Bioinformatics and Biomedical Engineering, IWBBIO 2022, Maspalomas, Spain, 2730 June 2022, VVolume 13346

[13] Doxil® - The first FDA-approved nano-drug: Lessons learned [J].

Barenholz, Yechezkel .

JOURNAL OF CONTROLLED RELEASE, 2012, 160 (02) :117-134

[14] AZD2171, a pan-VEGF receptor tyrosine kinase inhibitor, normalizes tumor vasculature and alleviates edema in glioblastoma patients [J].

Batchelor, Tracy T. ;

Sorensen, A. Gregory ;

di Tomaso, Emmanuelle ;

Zhang, Wei-Ting ;

Duda, Dan G. ;

Cohen, Kenneth S. ;

Kozak, Kevin R. ;

Cahill, Daniel P. ;

Chen, Poe-Jou ;

Zhu, Mingwang ;

Ancukiewicz, Marek ;

Mrugala, Maciej M. ;

Plotkin, Scott ;

Drappatz, Jan ;

Louis, David N. ;

Ivy, Percy ;

Scadden, David T. ;

Benner, Thomas ;

Loeffler, Jay S. ;

Wen, Patrick Y. ;

Jain, Rakesh K. .

CANCER CELL, 2007, 11 (01) :83-95

[15]

Batist Gerald, 2002, Expert Opin Pharmacother, V3, P1739, DOI 10.1517/14656566.3.12.1739

[16] Therapeutic Targeting of the Tumor Microenvironment [J].

Bejarano, Leire ;

Jordao, Marta J. C. ;

Joyce, Johanna A. .

CANCER DISCOVERY, 2021, 11 (04) :933-959

[17] Preclinical to Clinical Translation of Antibody-Drug Conjugates Using PK/PD Modeling: a Retrospective Analysis of Inotuzumab Ozogamicin [J].

Betts, Alison M. ;

Haddish-Berhane, Nahor ;

Tolsma, John ;

Jasper, Paul ;

King, Lindsay E. ;

Sun, Yongliang ;

Chakrapani, Subramanyam ;

Shor, Boris ;

Boni, Joseph ;

Johnson, Theodore R. .

AAPS JOURNAL, 2016, 18 (05) :1101-1116

[18]

Bhardwaj H, 2023, Next Nanotechnology, V2, P100013, DOI [10.1016/j.nxnano.2023.100013, 10.1016/j.nxnano.2023.100013, DOI 10.1016/J.NXNANO.2023.100013]

[19]

biofrontera, ABOUT US

[20]

Campbell Robert B., 2006, Anti-Cancer Agents in Medicinal Chemistry, V6, P503, DOI 10.2174/187152006778699077

← 1 2 3 4 5 6 7 8 9 10 →